We previously reviewed our study of the pharmacological properties of cardiac Na+/Ca2+ exchange (NCX1) inhibitors among cardioprotective drugs, such as amiodarone, bepridil, dronedarone, cibenzoline, azimilide, aprindine, and benzyl-oxyphenyl derivatives (Watanabe et al. in J Pharmacol Sci 102:7-16, 2006). Since then we have continued our studies further and found that some cardioprotective drugs are NCX1 stimulators. Cardiac Na+/Ca2+ exchange current (INCX1) was stimulated by nicorandil (a hybrid ATP-sensitive K+ channel opener), pinacidil (a non-selective ATP-sensitive K+ channel opener), flecainide (an antiarrhythmic drug), and sodium nitroprusside (SNP) (an NO donor). Sildenafil (a phosphodiesterase-5 inhibitor) further increased the pinacidil-induced augmentation of INCX1. In paper, here I review the NCX stimulants that enhance NCX function among the cardioprotective agents we examined such as nicorandil, pinacidil, SNP, sildenafil and flecainide, in addition to atrial natriuretic (ANP) and dofetilide, which were reported by other investigators.

中文翻译：

---

心脏保护药物之间的心脏Na + / Ca2 +交换刺激剂。

先前我们回顾了我们对心脏Na + / Ca2 +交换（NCX1）抑制剂在心脏保护药物（例如胺碘酮，贝普地尔，决奈达隆，环苯并林，阿齐米利，阿普林定和苄基氧苯基衍生物）中的药理特性的研究（Watanabe等人在《 J Pharmacol》中Sci 102：7-16，2006）。从那时起，我们进一步进行了研究，发现某些心脏保护药物是NCX1刺激物。尼可地尔（一种对ATP敏感的K +通道混合开放剂），吡那地尔（一种对ATP敏感的非选择性通道开放剂），氟卡尼（抗心律不齐的药物）和硝普钠（SNP）刺激心脏Na + / Ca2 +交换电流（INCX1）。 ）（无捐赠者）。西地那非（磷酸二酯酶5抑制剂）进一步增加了吡那地尔诱导的INCX1的增加。在纸上，